NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $5.99 +0.08 (+1.37%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Bolt Biotherapeutics Stock (NASDAQ:BOLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$5.92▼$6.1950-Day Range$3.35▼$6.5952-Week Range$3.10▼$7.78Volume7,350 shsAverage Volume92,357 shsMarket Capitalization$11.54 millionP/E RatioN/ADividend YieldN/APrice Target$14.50Consensus RatingHold Company Overview Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response. The company has also pursued myeloid cell engager therapies designed to activate macrophages and other immune cells against cancer. Its development programs have included BDC-1001, an investigational HER2-targeted ISAC evaluated in patients with HER2-expressing solid tumors, and BDC-3042, an investigational myeloid engager intended for use in combination with other cancer immunotherapies. Bolt Biotherapeutics was founded in 2015 and is headquartered in Redwood City, California. Its programs have been evaluated through clinical studies involving patients with advanced solid tumors.AI Generated. May Contain Errors. Read More Bolt Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreBOLT MarketRank™: 3.74148322851 of 5 starsBolt Biotherapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 143rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBolt Biotherapeutics has a consensus price target of $14.50, representing about 142.0% upside from its current price of $5.99.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.72% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently increased by 200.82%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth.Read more about Bolt Biotherapeutics' dividend. News and Social Media3.8 / 5News Sentiment1.10 News SentimentBolt Biotherapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Bolt Biotherapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $190,639.00 in company stock, which represents 1.6522% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have bought 148.52% more of their company's stock than they have sold. Specifically, they have bought $319,000.00 in company stock and sold $128,361.00 in company stock.Percentage Held by Insiders9.40% of the stock of Bolt Biotherapeutics is held by insiders.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLT Stock News HeadlinesBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Report for OctoberNovember 13 at 1:41 AM | americanbankingnews.comBolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12 at 4:05 PM | globenewswire.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 13 at 1:00 AM | Traders Agency (Ad)Bolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Purchases 50,000 Shares of Company StockNovember 11 at 5:37 AM | insidertrades.comBolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on WednesdayNovember 10 at 3:43 AM | americanbankingnews.comINVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?November 4, 2026 | globenewswire.comBolt Biotherapeutics to Participate in Upcoming ConferencesNovember 3, 2026 | globenewswire.comBolt Biotherapeutics consensus price target increased by 1,400% to $76.50November 2, 2026 | msn.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $5.47 at the beginning of the year. Since then, BOLT stock has increased by 9.5% and is now trading at $5.9910. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) posted its earnings results on Thursday, November, 12th. The company reported ($2.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.68) by $1.43. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative trailing twelve-month return on equity of 126.23%. When did Bolt Biotherapeutics' stock split? Bolt Biotherapeutics's stock reverse split before market open on Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $213 million in an IPO on Friday, February 5th 2021. The company issued 11,500,000 shares at a price of $18.00-$19.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include onsemi (ON), Enterprise Products Partners (EPD), NIO (NIO), Energy Transfer (ET), Achilles Therapeutics (ACHL), Aldeyra Therapeutics (ALDX) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/12/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, BOLT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CIK1641281 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees23Year Founded2015Price Target and Rating Average Price Target for Bolt Biotherapeutics$14.50 High Price Target$22.00 Low Price Target$7.00 Potential Upside/Downside+141.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($16.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.38 million Net Margins-611.47% Pretax Margin-611.47% Return on Equity-126.23% Return on Assets-54.70% Debt Debt-to-Equity Ratio1.47 Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual Sales$4.70 million Price / Sales2.46 Cash FlowN/A Price / Cash FlowN/A Book Value$13.81 per share Price / Book0.44Miscellaneous Outstanding Shares1,926,000Free Float1,745,000Market Cap$11.58 million OptionableNot Optionable Beta0.85 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BOLT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLT Stock Alerts